Who
Arun Swaminathan
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Coya Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 2
- Sells
- 0
- Bought
- $74K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Nov 2024
- Last trade
- 22 Jan 2026
- Last filed
- 26 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jan 2026filed 26 Jan 2026 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —293,983 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —293,983 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,964 at $0.00 | filing |
| 13 Nov 2024filed 13 Nov 2024 | COYA Coya TherapeuticsBiotechnology | SEC FORM 4 Bought | $37K5,000 at $7.36 | filing |
| 11 Nov 2024filed 12 Nov 2024 | COYA Coya TherapeuticsBiotechnology | SEC FORM 4 Bought | $37K5,000 at $7.34 | filing |
News
Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastCOYA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Arun Swaminathan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.